Generic name for valsartan
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Generic Name for Valsartan: An Overview
Introduction to Valsartan
Valsartan is a widely used antihypertensive medication that belongs to the class of drugs known as angiotensin II receptor blockers (ARBs). It is primarily prescribed for the treatment of high blood pressure, congestive heart failure, and for patients recovering from a myocardial infarction.
Development and Patent History
Valsartan was developed in the 1990s and was initially patented by Novartis Pharmaceuticals under the brand name Diovan. The patent for Diovan expired in the United States in 2012, allowing valsartan to be marketed as a generic drug by various pharmaceutical companies.
Generic Valsartan and Market Availability
Following the expiration of the patent, valsartan became available as a generic medication. It is now sold by multiple companies, making it more accessible and affordable for patients. However, the transition to generic versions has not been without challenges. For instance, a significant recall of generic valsartan occurred in 2018 due to contamination with N-nitrosodimethylamine (NDMA), a potential carcinogen, which affected numerous generic formulations.
Bioequivalence Studies
Bioequivalence studies are crucial to ensure that generic versions of valsartan are as effective and safe as the original branded version. A study conducted in India compared the pharmacokinetic properties of two branded generic formulations of valsartan with the original branded product. The study found that one of the generic formulations was bioequivalent to the branded version, while the other was not, highlighting the importance of rigorous testing for generic drugs.
Conclusion
The generic name for valsartan remains valsartan, and it is marketed under various brand names following the expiration of the original patent. Despite some challenges, such as the 2018 recall, generic valsartan continues to be a vital medication for managing hypertension and related conditions. Ensuring bioequivalence and safety of generic formulations is essential for maintaining the trust and health of patients.
Sources and full results
Most relevant research papers on this topic